Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Hansa Biopharma
  4. Hansa Biopharma — November 2021

Hansa Biopharma — November 2021

Planlagt Fastgjort Låst Flyttet Hansa Biopharma
48 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #14

    Ja. Oncopeptides er oppe med +35% idag. Short er godt brændstof til en hurtig stigning.

    1 Reply Last reply
    0
    • exitnuE Offline
      exitnuE Offline
      exitnu
      wrote on sidst redigeret af
      #15

      Beklager dobbelt posting!

      1 Reply Last reply
      0
      • A Offline
        A Offline
        Aps_invest
        wrote on sidst redigeret af
        #16

        Hansa Biopharma AB: Hansa Biopharma avser att initiera en fas 3-studie med imlifidase för behandling av anti-GBM-sjukdom efter framgångsrikt rådgivningsmöte med FDA i USA

        1 Reply Last reply
        0
        • exitnuE Offline
          exitnuE Offline
          exitnu
          wrote on sidst redigeret af
          #17

          Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA

          https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-to-initiate-Phase-3-study-of-imlifidase-to-treat-anti-Glomerular-Basement-Membrane-anti-GBM-disease-after-successful-pre-IND-meeting-with-U.S.-FDA/default.aspx

          (11/15/2021)

          1 Reply Last reply
          0
          • exitnuE Offline
            exitnuE Offline
            exitnu
            wrote on sidst redigeret af
            #18

            "Den nu avslutade fas 2-studien visade att två tredjedelar av patienterna inte behövde dialys sex månader efter behandling med imlifidase. Detta positiva resultat validerar imlifidase som en potentiell behandling av allvarliga IGG-medierade autoimmuna sjukdomar, skriver Hansa Biopharma."

            Super!

            1 Reply Last reply
            0
            • A Offline
              A Offline
              Aps_invest
              wrote on sidst redigeret af
              #19

              Er MSE ved at lukke deres shorts? De har også bombet kursen langt ned over lang tid, og begynder måske at lukke nogle shorts. Lad os se, de giver nok ikke så let op.

              1 Reply Last reply
              0
              • A Offline
                A Offline
                Aps_invest
                wrote on sidst redigeret af
                #20

                Så shorter MSE igen....møgirriterende som de bomber Hansa.

                1 Reply Last reply
                0
                • exitnuE Offline
                  exitnuE Offline
                  exitnu
                  wrote on sidst redigeret af
                  #21

                  Det får en ende på et tidspunkt, gode og gerne flere nyheder kan ikke holde kursen nede på sigt 🙂

                  1 Reply Last reply
                  0
                  • exitnuE Offline
                    exitnuE Offline
                    exitnu
                    wrote on sidst redigeret af
                    #22

                    Oncopeptides er oppe med 36% - blot for at sige at shorts OGSÅ kan udløse pæne kursstigninger.

                    1 Reply Last reply
                    0
                    • exitnuE Offline
                      exitnuE Offline
                      exitnu
                      wrote on sidst redigeret af
                      #23

                      Hansa Biopharma; FDA opens the door for the next pivotal Phase 3 study

                      Just a moment...

                      favicon

                      (www.redeye.se)

                      1 Reply Last reply
                      0
                      • exitnuE Offline
                        exitnuE Offline
                        exitnu
                        wrote on sidst redigeret af
                        #24

                        Uddrag:

                        "In our view, Hansa Biopharma’s ability to progress the progress of the anti-GBM opportunity for the imlifidase platform is distinctly positive. This follows a successful pre-IND meeting with the FDA. Recently we have seen several FDA delays in this sector, and Hansa’s ability to timely progress this candidate to the third pivotal Phase 3 trial is an achievement."

                        1 Reply Last reply
                        0
                        • exitnuE Offline
                          exitnuE Offline
                          exitnu
                          wrote on sidst redigeret af
                          #25

                          "....... Our base case value proposition is SEK 410 (Bear SEK 175 and Bull SEK 600)."

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            Munchi
                            wrote on sidst redigeret af
                            #26

                            ja vildt at den stadig kan købes for en svensk hund...

                            1 Reply Last reply
                            0
                            • exitnuE Offline
                              exitnuE Offline
                              exitnu
                              wrote on sidst redigeret af
                              #27

                              Shorterne taber kampen til sidst 🙂

                              1 Reply Last reply
                              0
                              • exitnuE Offline
                                exitnuE Offline
                                exitnu
                                wrote on sidst redigeret af
                                #28

                                Vælg: Blankningspositioner i Hansa Biopharma AB

                                Link Preview Image
                                Blankningsregister.se

                                Ett register över blankningspositioner i noterade bolag. Här publiceras korta positioner från 0,2% och uppåt.

                                favicon

                                (www.blankningsregister.se)

                                1 Reply Last reply
                                0
                                • exitnuE Offline
                                  exitnuE Offline
                                  exitnu
                                  wrote on sidst redigeret af
                                  #29

                                  Hansa Biopharma to start Phase III anti-GBM disease therapy trial

                                  Link Preview Image
                                  Hansa Biopharma to start Phase III anti-GBM disease therapy trial

                                  Hansa has decided to begin the Phase III trial of imlifidase for the treatment of anti-Glomerular Basement Membrane (anti-GBM) disease.

                                  favicon

                                  Clinical Trials Arena (www.clinicaltrialsarena.com)

                                  (Clinicaltrialsarena)

                                  1 Reply Last reply
                                  0
                                  • exitnuE Offline
                                    exitnuE Offline
                                    exitnu
                                    wrote on sidst redigeret af
                                    #30

                                    Så er Oncopeptides ope med +43% ... hårdt at være short ...

                                    1 Reply Last reply
                                    0
                                    • exitnuE Offline
                                      exitnuE Offline
                                      exitnu
                                      wrote on sidst redigeret af
                                      #31

                                      Oncopeptides er iøvrigt gået fra kurs 3,83 (1. november) til over kurs 10 idag +161%.

                                      1 Reply Last reply
                                      0
                                      • A Offline
                                        A Offline
                                        Aps_invest
                                        wrote on sidst redigeret af
                                        #32

                                        Hvad kunne være en realistisk kurstrigger, som kunne give shorterne i Hansa lidt tynd mave? 🙂

                                        1 Reply Last reply
                                        0
                                        • exitnuE Offline
                                          exitnuE Offline
                                          exitnu
                                          wrote on sidst redigeret af
                                          #33

                                          Der er mange men helt basalt: FDA godkendelser, pipeline-nyheder, M&A, gode salgstal, partneraftaler, nyt omkring prækliniske studier, initieringer af fase 1-2-3 studier eller udbetaling af milestones.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper